Pascal Deschatelets - Jul 8, 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Scientific Officer
Signature
/s/ David Watson, attorney-in-fact for Pascal Deschatelets
Stock symbol
APLS
Transactions as of
Jul 8, 2022
Transactions value $
-$526,005
Form type
4
Date filed
7/12/2022, 04:04 PM
Previous filing
Jun 22, 2022
Next filing
Aug 9, 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $32K +12K +1.29% $2.67* 943K Jul 8, 2022 Direct F1
transaction APLS Common Stock Options Exercise $17.4K +6.5K +0.69% $2.67* 950K Jul 8, 2022 Direct F2
transaction APLS Common Stock Sale -$575K -12K -1.26% $47.95 938K Jul 8, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -12K -3.83% $0.00 301K Jul 8, 2022 Common Stock 12K $2.67 Direct F1, F3
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -6.5K -2.16% $0.00 295K Jul 8, 2022 Common Stock 6.5K $2.67 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This is a scheduled exercise and sale from a 10B5-1 trading plan.
F2 This is a scheduled exercise from 10B5-1 trading plan.
F3 This stock option was granted on 12/5/2013 and is fully vested.